Physician profile
Dean E Caven
NPI 1740227537
$2,510.19
in general payments reported to CMS, 2019-2025
29 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $23.68 · 2021: $195 · 2022: $313 · 2023: $445 · 2024: $401 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.14 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $443.63 | 2019-2025 | Lifevest |
| Pfizer INC. | $292.75 | 2019-2025 | |
| Boston Scientific Corporation | $245.87 | 2019-2025 | Watchman Flx, General - Ep |
| Abbott Laboratories | $219.89 | 2019-2025 | Aveir, Jot Dx |
| E.R. Squibb & Sons, L.L.C. | $183.79 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.12 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $117.58 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $117.38 | 2023 | Opsumit, Uptravi |
| Amgen INC. | $111.58 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $80.71 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $50.46 | 2023-2024 | Onpattro |
| Edwards Lifesciences Corporation | $46.00 | 2019 | |
| Amarin Pharma, INC. | $44.58 | 2019 | |
| Philips North America LLC | $43.49 | 2023-2025 | Holter |
| Kestra Medical Technology Services, INC. | $42.19 | 2023-2025 | Assure Wcd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.43 | 2022-2025 | Verquvo, Capvaxive |
| Medtronic, INC. | $41.11 | 2021-2022 | |
| Novo Nordisk INC | $38.12 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $27.41 | 2019 | |
| Heartflow, INC. | $24.89 | 2025 | |
| Cvrx, INC. | $22.18 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $20.87 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $19.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.32 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $18.80 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $18.55 | 2021 | |
| Atricure, INC. | $17.56 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Kowa Pharmaceuticals America, INC. | $14.34 | 2019 | |
| Medtronic Vascular, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Caven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.